CNTB
Connect BiopharmaCNTB
CNTB
About: Connect Biopharma Holdings Ltd is a clinical-stage company focused on the discovery and development of next-generation immune modulators for the treatment of serious autoimmune diseases and inflammation. It has leveraged its expertise in the biology of T cell modulation to build a portfolio of drug candidates consisting of small molecules and antibodies targeting critical pathways of inflammation. Its pipeline includes CBP-201, CBP-307 and CBP-174.
Employees: 62
0
Funds holding %
of 7,296 funds
–
Analysts bullish %
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
0.64% less ownership
Funds ownership: 5.76% [Q4 2024] → 5.12% (-0.64%) [Q1 2025]
7% less funds holding
Funds holding: 14 [Q4 2024] → 13 (-1) [Q1 2025]
50% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 2
64% less capital invested
Capital invested by funds: $4.37M [Q4 2024] → $1.56M (-$2.82M) [Q1 2025]
75% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 4
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$7
637%
upside
Avg. target
$7.50
689%
upside
High target
$8
742%
upside
2 analyst ratings
2 positive
100%
0 neutral
0%
0 negative
0%
HC Wainwright & Co. Brandon Folkes | 637%upside $7 | Buy Assumed | 12 Jun 2025 |
HC Wainwright & Co. Emily Bodnar | 742%upside $8 | Buy Reiterated | 1 Apr 2025 |
Financial journalist opinion
Based on 4 articles about CNTB published over the past 30 days
Neutral
GlobeNewsWire
2 days ago
Connect Biopharma Presents Data Supporting Rademikibart at the European Academy of Allergy and Clinical Immunology (EAACI) 2025 Annual Congress
– Rademikibart significantly improved lung function and asthma control in patients with eosinophilic-driven type 2 asthma –
Neutral
GlobeNewsWire
1 week ago
Connect Biopharma Announces Two Oral Presentations at the European Academy of Allergy and Clinical Immunology (EAACI) 2025 Annual Congress
SAN DIEGO, June 03, 2025 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (“Connect Biopharma” or the “Company”), a clinical-stage biopharmaceutical company focused on transforming acute and chronic care of asthma and chronic obstructive pulmonary disease (COPD), today announced two oral presentations at the European Academy of Allergy and Clinical Immunology (EAACI) 2025 Annual Congress, taking place June 13-16, 2025, in Glasgow, United Kingdom and virtually.
Neutral
GlobeNewsWire
2 weeks ago
Connect Biopharma to Present at Two Upcoming Investor Conferences in June
SAN DIEGO, May 28, 2025 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (“Connect Biopharma” or the “Company”), a clinical-stage biopharmaceutical company focused on transforming acute and chronic care of asthma and chronic obstructive pulmonary disease (COPD), today announced that company management will participate in the following upcoming conferences: Noble Capital Markets Virtual Conference Format: Corporate PresentationDate: Wednesday, June 4th, 2025Time: 9:00 a.m. ET Jefferies Healthcare Conference Format: Corporate PresentationDate: Thursday, June 5th, 2025Time: 7:35 a.m.
Neutral
GlobeNewsWire
3 weeks ago
Connect Biopharma Presents Data Supporting Development of Rademikibart at the American Thoracic Society (ATS) 2025 International Conference
– Rademikibart significantly improved airway function, as measured by FEV 1 , within a day and significantly reduced acute exacerbations in patients with inflammation-mediated chronic asthma strongly supporting ongoing Phase 2 acute exacerbation studies in asthma and COPD which are expected to report topline data in 1H26 – – New preclinical data highlights differentiated st ructural and molecular dynamics of rademikibart with enhanced interleukin-4 receptor alpha (IL-4Rα) inhibition compared to dupilumab providing a molecular basis for the differentiated efficacy and safety observed with rademikibart presented at this meeting – SAN DIEGO, May 20, 2025 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (Connect Biopharma, Connect or the Company), a clinical-stage biopharmaceutical company focused on transforming acute and chronic care of asthma and chronic obstructive pulmonary disease (COPD), today announced clinical and preclinical data supporting rademikibart, the Company's next-generation, potentially best-in-class anti-interleukin-4-receptor alpha (IL-4Rα) antibody, which was presented at the American Thoracic Society (ATS) 2025 International Conference, taking place from May 18-21, 2025, in San Francisco. “We are pleased to share new clinical and preclinical data highlighting rademikibart's potential as a best-in-class treatment for patients with asthma or COPD experiencing an acute exacerbation,” said Barry Quart, Pharm.D.
Neutral
GlobeNewsWire
1 month ago
Connect Biopharma Reports First Quarter 2025 Financial Results and Provides Business Update
Initiated Phase 2 Seabreeze STAT Asthma and Seabreeze STAT COPD studies evaluating rademikibart as an adjunct treatment for acute exacerbations in Asthma and COPD in May 2025; topline data expected in 1H 2026 Published positive data from its global Phase 2 study supporting potential of rademikibart as a novel biologic treatment for patients with asthma and Type 2 inflammation Strong balance sheet with cash runway into 2027 through key clinical catalysts SAN DIEGO, May 15, 2025 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (Connect Biopharma, Connect or the Company), a clinical-stage biopharmaceutical company focused on transforming acute and chronic care of asthma and chronic obstructive pulmonary disease (COPD), today reported financial results for the three months ended March 31, 2025, and provided a business update. “The first quarter of 2025 was very productive, including a positive Type C meeting with the U.S. Food and Drug Administration (FDA), publication of our previously completed global Phase 2 trial results in the American Journal of Respiratory and Critical Care Medicine (AJRCCM), and acceptance of four posters to be presented at the American Thoracic Society (ATS) 2025 International Conference,” said Barry Quart, Pharm.D.
Neutral
GlobeNewsWire
1 month ago
Connect Biopharma Initiates Phase 2 Seabreeze STAT COPD Study Evaluating Rademikibart for the Treatment of Acute Exacerbations in COPD
– Expect to report topline data from the Seabreeze STAT COPD study in 1H 2026 – SAN DIEGO, May 14, 2025 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (Connect Biopharma, Connect or the Company), a clinical-stage biopharmaceutical company focused on transforming acute and chronic care of asthma and chronic obstructive pulmonary disease (COPD), today announced the initiation of its Phase 2 Seabreeze STAT COPD study (NCT06940154) following written agreement on the final study protocol from the U.S. Food and Drug Administration. The study will evaluate the safety and efficacy of rademikibart as an adjunct to standard of care for acute exacerbations in participants with COPD and type 2 inflammation.
Neutral
GlobeNewsWire
1 month ago
Connect Biopharma Initiates Phase 2 Seabreeze STAT Asthma Study Evaluating Rademikibart for the Treatment of Acute Exacerbations in Asthma
– Expect to report topline data from the Seabreeze STAT Asthma study in 1H 2026 – – On track to initiate similarly-designed Phase 2 study in patients with COPD imminently – SAN DIEGO, May 13, 2025 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (Connect Biopharma, Connect or the Company), a clinical-stage biopharmaceutical company focused on transforming acute and chronic care of asthma and chronic obstructive pulmonary disease (COPD), today announced the initiation of its Phase 2 Seabreeze STAT Asthma study (NCT06940141) following written agreement on the final study protocol from the U.S. Food and Drug Administration. The study will evaluate the safety and efficacy of rademikibart as an adjunct to standard of care for acute exacerbations in adults and adolescent participants with asthma and type 2 inflammation.
Neutral
GlobeNewsWire
1 month ago
Connect Biopharma Announces Multiple Presentations at the American Thoracic Society (ATS) 2025 International Conference
– Data to be presented supports development of rademikibart for patients with moderate-to-severe asthma or COPD experiencing an acute exacerbation – – Advancing rapid clinical development plan for rademikibart; expect to initiate parallel Phase 2 trials in 2Q25 – SAN DIEGO, April 24, 2025 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (Connect Biopharma or the Company), a clinical-stage biopharmaceutical company focused on transforming acute and chronic care of asthma and chronic obstructive pulmonary disease (COPD), today announced the Company will present four posters at the American Thoracic Society (ATS) 2025 International Conference, taking place May 18-21, 2025, in San Francisco. The following abstracts are posted on ATS 2025's online itinerary planner for registered users: Title: Efficacy of Rademikibart in COPD-like Patients: Sub-analyses From the Phase 2b Trial in Patients with Moderate-to-Severe Asthma Presenter: Raúl Collazo, Ph.D.
Neutral
GlobeNewsWire
2 months ago
Connect Biopharma Announces Positive Type C Meeting with the FDA for Rademikibart
– FDA aligned on plan to initiate parallel Phase 2 trials of rademikibart in patients with moderate-to-severe asthma or COPD experiencing an acute exacerbation – – Expect to initiate both trials in Q2 2025 – SAN DIEGO, April 01, 2025 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (Connect or Connect Biopharma), a clinical-stage biopharmaceutical company focused on transforming acute and chronic care of asthma and chronic obstructive pulmonary disease (COPD), today announced positive feedback from its Type C meeting with the U.S. Food and Drug Administration (FDA), Division of Pulmonology, Allergy, and Critical Care, in the Office of Immunology and Inflammation. “We are pleased to have the FDA's alignment on our two parallel Phase 2 trials evaluating rademikibart in patients experiencing an acute exacerbation of asthma or COPD, an area where no biologic therapies have been approved or systematically studied,” said Barry Quart, Pharm.D.
Neutral
GlobeNewsWire
2 months ago
Connect Biopharma Announces Publication of Positive Data from Global Phase 2 Trial of Rademikibart in Patients with Moderate-to-Severe Uncontrolled Asthma
– Rademikibart demonstrated rapid onset of action with significant improvements in lung function observed at one week and maintained through 24 weeks – – In patients with eosinophilic-driven asthma (≥300 eosinophils/µL) receiving rademikibart for 24 weeks, the mean difference from placebo in forced expiratory volume was +420 mL, amongst the largest increases reported for a biologic – SAN DIEGO, March 31, 2025 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (Connect Biopharma), a clinical-stage biopharmaceutical company focused on transforming acute and chronic care of asthma and Chronic Obstructive Pulmonary Disease (COPD), today announced the online publication of positive results from the global Phase 2 trial of rademikibart in patients with moderate-to-severe uncontrolled asthma in the American Journal of Respiratory and Critical Care Medicine (AJRCCM). These data highlight rademikibart's potential as a novel biologic treatment option for patients with asthma and Type 2 inflammation, demonstrating rapid onset of action, sustained improvement in forced expiratory volume in one second (FEV1), and clinically important reductions in annual exacerbation rates.
Charts implemented using Lightweight Charts™